Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients

被引:37
|
作者
Mei, Fei [1 ]
Fan, Jiawei [1 ]
Yuan, Jinhua [1 ]
Liang, Zhenzhen [2 ]
Wang, Kewei [1 ]
Sun, Jianfeng [1 ]
Guan, Wenfei [1 ]
Huang, Mingkui [1 ]
Li, Yu [1 ]
Zhang, Wayne W. [3 ,4 ]
机构
[1] China Three Gorges Univ, Yichang Cent Peoples Hosp, Coll Clin Med Sci 1, Dept Vasc Surg, Yichang, Hubei, Peoples R China
[2] Jilin Univ, Key Lab Radiobiol, Natl Hlth Commiss, Changchun, Jilin, Peoples R China
[3] Univ Washington, Dept Surg, Div Vasc & Endovasc Surg, Seattle, WA 98108 USA
[4] Puget Sound VA Hlth Care Syst, Seattle, WA USA
关键词
critical illness; hospital mortality; incidence; pneumonia; venous thromboembolism; ACUTE RESPIRATORY SYNDROME;
D O I
10.1161/ATVBAHA.120.314779
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objectives were to investigate and compare the risks and incidences of venous thromboembolism (VTE) between the 2 groups of patients with coronavirus disease 2019 (COVID-19) pneumonia and community-acquired pneumonia (CAP). Approach and Results: Medical records of 616 pneumonia patients who were admitted to the Yichang Central People's Hospital in Hubei, China, from January 1 to March 23, 2020, were retrospectively reviewed. The patients with COVID-19 pneumonia were treated in the dedicated COVID-19 units, and the patients with CAP were admitted to regular hospital campus. Risks of VTE were assessed using the Padua prediction score. All the patients received pharmaceutical or mechanical VTE prophylaxis. VTE was diagnosed using Duplex ultrasound or computed tomography pulmonary angiogram. Differences between COVID-19 and CAP groups were compared statistically. All statistical tests were 2 sided, andP<0.05 was considered as statistically significant. All data managements and analyses were performed by IBM SPSS, version 24, software (SPSS, Inc, Chicago, IL). Of the 616 patients, 256 had COVID-19 pneumonia and 360 patients had CAP. The overall rate of VTE was 2% in COVID-19 pneumonia group and 3.6% in CAP group, respectively (P=0.229). In these two groups, 15.6% of the COVID-19 pneumonia patients and 10% of the CAP patients were categorized as high risk for VTE (Padua score, >4), which were significantly different (P=0.036). In those high-risk patients, the incidence of VTE was 12.5% in COVID-19 pneumonia group and 16.7% in CAP group (P=0.606). Subgroup analysis of the critically ill patients showed that VTE rate was 6.7% in COVID-19 group versus 13% in CAP group (P=0.484). In-hospital mortality of COVID-19 and CAP was 6.3% and 3.9%, respectively (P=0.180). Conclusions: Our study suggested that COVID-19 pneumonia was associated with hypercoagulable state. However, the rate of VTE in COVID-19 pneumonia patients was not significantly higher than that in CAP patients.
引用
收藏
页码:2332 / 2337
页数:6
相关论文
共 50 条
  • [1] Letter by Hamilton et al Regarding Article, "Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients"
    Hamilton, David O.
    Waite, Alicia A. C.
    Welters, Ingeborg D.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (11) : E309 - E310
  • [2] Clinical Differences between Community-Acquired Mycoplasma pneumoniae Pneumonia and COVID-19 Pneumonia
    Miyashita, Naoyuki
    Nakamori, Yasushi
    Ogata, Makoto
    Fukuda, Naoki
    Yamura, Akihisa
    Ishiura, Yoshihisa
    Nomura, Shosaku
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [3] Patients with COVID-19 versus non-COVID-19 community-acquired pneumonia
    Liapikou, A.
    Milionis, H.
    Liontos, A.
    Tsimihodimos, V
    Konstantinidis, A.
    Exarchos, K.
    Gartzonika, K.
    Kittas, C.
    Baxevanos, G.
    Tzimas, T.
    Chrysostomou, E.
    Zotos, N.
    Papageorgiou, L.
    Terrovitou, C.
    Daniilidis, D.
    Triantafyllidis, C.
    Argiriadou, T.
    Chli, A.
    Tsouchnika, E.
    Kossyvaki, V
    Skiadas, J.
    Menegas, D.
    Mendez, C.
    Schwarz, C.
    Begier, E.
    Gessner, B. D.
    Toumbis, M.
    Konstantinidis, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [4] Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia
    Kuluozturk, Mutlu
    In, Erdal
    Telo, Selda
    Karabulut, Ercan
    Geckil, Aysegul Altintop
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (05) : 3113 - 3121
  • [5] Lung Ultrasound Segmentation and Adaptation Between COVID-19 and Community-Acquired Pneumonia
    Mason, Harry
    Cristoni, Lorenzo
    Walden, Andrew
    Lazzari, Roberto
    Pulimood, Thomas
    Grandjean, Louis
    Wheeler-Kingshott, Claudia A. M. Gandini
    Hu, Yipeng
    Baum, Zachary M. C.
    SIMPLIFYING MEDICAL ULTRASOUND, 2021, 12967 : 45 - 53
  • [6] Lipidomic and metabolomic changes in community-acquired and COVID-19 pneumonia
    Saballs, Mireia
    Parra, Sandra
    Martinez, Neus
    Amigo, Nuria
    Cabau, Lydia
    Iftimie, Simona
    Pavon, Raul
    Gabaldo, Xavi
    Correig, Xavier
    Paredes, Silvia
    Vallve, Josep Maria
    Castro, Antoni
    JOURNAL OF LIPID RESEARCH, 2024, 65 (09)
  • [7] Severe community-acquired pneumonia in the post COVID-19 era
    Ruiz-Spinelli, Alfonsina
    Waterer, Grant
    Rello, Jordi
    CURRENT OPINION IN CRITICAL CARE, 2023, 29 (05) : 400 - 406
  • [8] A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia
    Jaoude, Philippe
    Badlam, Jessica
    Anandam, Anil
    El-Solh, Ali A.
    INTERNAL AND EMERGENCY MEDICINE, 2014, 9 (02) : 143 - 150
  • [9] A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia
    Philippe Jaoude
    Jessica Badlam
    Anil Anandam
    Ali A. El-Solh
    Internal and Emergency Medicine, 2014, 9 : 143 - 150
  • [10] Features Discriminating COVID-19 From Community-Acquired Pneumonia in Pediatric Patients
    Guo, Yu
    Xia, Wei
    Peng, Xuehua
    Shao, Jianbo
    FRONTIERS IN PEDIATRICS, 2020, 8